Molecular Features of Alzheimer's Disease and Neurodegenerative Disorder

P Minor^*
*Correspondence: P Minor, Department of Virology, Public University of Liverpool, Liverpool, UK, Email:

Keywords

Molecules • Brain • Alzheimer's disease • Immune cells • DNA methylation • Apolipoprotein E

Introduction

Recent research has identified a number of genetic risk factors for Alzheimer's disease. One of the most well-known of these risk factors is the presence of the Apolipoprotein E (APOE) ε4 allele. APOE is a gene that encodes a protein involved in the transport of lipids in the body. The ε4 allele is associated with an increased risk of Alzheimer's disease, and individuals with two copies of the allele have a significantly higher risk of developing the disease compared to individuals with no copies or one copy of the allele.

In addition to APOE, a number of other genes have been identified that are associated with an increased risk of Alzheimer's disease. These include genes involved in the processing such as APP, β- secretase (BACE1), and γ-secretase (PSEN1 and PSEN2). Mutations in these genes can lead to the overproduction or the production of more toxic [1].

Literature Review

Another genetic risk factor for Alzheimer's disease is the presence of mutations in the gene encoding tau, a protein that is involved in the formation of neurofibrillary tangles in the brain. Tau is normally involved in the stabilization of microtubules, which are important structures that help maintain the shape and function of neurons. However, in Alzheimer's disease, tau becomes abnormally phosphorylated, leading to the formation of neurofibrillary tangles that are toxic to neurons.

Recent research has also identified a number of epigenetic factors that may play a role in the development of Alzheimer's disease. Epigenetic modifications are changes to the structure or function of DNA that do not involve changes to the DNA sequence itself. One of the most well-known epigenetic modifications is DNA methylation, which involves the addition of a methyl group to a cytosine base in DNA. DNA methylation can affect gene expression and has been linked to a number of different diseases, including Alzheimer's disease.

In a recent study, researchers found that DNA methylation patterns in the brains of individuals with Alzheimer's disease were significantly different from those in healthy individuals. Specifically, they found that DNA methylation was decreased in genes involved in the regulation of immune responses, suggesting that changes to the immune system may be involved in the development of Alzheimer's disease [2].

Discussion

Other epigenetic modifications that have been linked to Alzheimer's disease include changes to histone proteins, which are involved in the packaging of DNA in the nucleus, and alterations to non-coding RNAs, which are involved in the regulation of gene expression. These epigenetic modifications may be involved in the regulation of genes that are important in the development and progression of Alzheimer's disease.

In addition to genetic and epigenetic factors, a number of environmental and lifestyle factors have been linked to an increased risk of Alzheimer's disease.

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide. The disease is characterized by the accumulation of protein aggregates in the brain, which leads to the loss of neurons and cognitive decline. While the exact cause of Alzheimer's disease is not yet fully understood, research in the fields of molecular biology and genetics has provided important insights into the underlying mechanisms of the disease [3].

One of the key molecular features of Alzheimer's disease is the accumulation of amyloid-beta peptides in the brain. Peptides are derived from a larger protein called Amyloid Precursor Protein (APP), which is found on the surface of neurons. Normally, APP is cleaved by enzymes to produce smaller fragments that are either degraded or recycled. However, in Alzheimer's disease, APP is cleaved in a different way, producing peptides that are prone to aggregation.

The accumulation peptides in the brain are thought to be a key driver of Alzheimer's disease pathology. These peptides can form aggregates called amyloid plaques, which are thought to be toxic to neurons. The precise mechanisms by which amyloid plaques cause neuronal damage are not yet fully understood, but it is thought that they disrupt normal cellular processes and lead to inflammation and oxidative stress.

A number of different genetic factors have been implicated in the development of Alzheimer's disease. One of the most wellknown of these is the APOE gene, which encodes a protein called apolipoprotein E. APOE comes in several different variants, the most common of which are APOE2, APOE3, and APOE4. APOE4 is associated with an increased risk of Alzheimer's disease, while APOE2 appears to be protective [4].

The precise mechanisms by which APOE4 contributes to Alzheimer's disease are not yet fully understood, but it is thought to be related to the role of Apolipoprotein E in lipid metabolism and inflammation. APOE4 has been shown to be less effective than APOE2 and APOE3 at clearing peptides from the brain, and it may also be more prone to forming toxic aggregates.

Another genetic factor that has been implicated in Alzheimer's disease is the presenilin gene. Mutations in the presently gene have been found in rare cases of familial Alzheimer's disease, which is a type of Alzheimer's disease that is caused by a genetic mutation rather than by environmental factors. Presenilin is involved in the processing of APP, and mutations in the presenilin gene are thought to lead to the production of more toxic forms peptides.

Research in the field of molecular biology has provided important insights into the mechanisms by peptides are generated and processed in the brain. One key pathway is the amyloidogenic pathway, which leads to the production peptides that are prone to aggregation. The amyloidogenic pathway involves the cleavage of APP by an enzyme called beta-secretase (BACE) and another enzyme called gamma-secretase. Drugs that inhibit BACE or gamma-secretase are being developed as potential therapies for Alzheimer's disease [5].

Another pathway is the non-amyloidogenic pathway, which produces smaller fragments of APP that are less prone to aggregation. This pathway is thought to be protective against Alzheimer's disease, and drugs that promote the non-amyloidogenic pathway are also being developed as potential therapies.

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that is characterized by the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain. The genetics and molecular biology of AD has been the subject of extensive research in recent years, as scientists seek to better understand the underlying mechanisms of the disease and to develop new treatments.

Approximately 5% of AD cases are inherited in an autosomal dominant pattern, caused by mutations in one of three genes: Amyloid Precursor Protein (APP), Presenilin-1 (PSEN1), or Presenilin-2 (PSEN2). These mutations result in an overproduction of which leads to the formation plaques in the brain.

The majority of AD cases, however, are sporadic, with no clear genetic component. However, several genes have been identified that are associated with an increased risk of developing AD. One of the most well-known of these genes is the apolipoprotein E (APOE) gene, which has three common alleles. Individuals who inherit one or two copies of the ε4 allele have an increased risk of developing AD, while individuals with the ε2 allele may have a decreased risk [6].

Conclusion

Other genes that have been associated with an increased risk of AD include Clusterin (CLU), Phosphatidylinositol Binding Clathrin Assembly Protein (PICALM), Bridging Integrator 1 (BIN1), Complement Receptor 1 (CR1), and Sortilin-Related Receptor 1 (SORL1). Many of these genes are involved in the clearance and processing of in the brain. The molecular biology of AD is complex and involves a number of different processes, including clearance, tau hyper phosphorylation, inflammation, and oxidative stress.

Inhibition of potential therapeutic approach for treating AD. However, both enzymes have other functions in the body, so complete inhibition may have unwanted side effects. Brain is an important mechanism for preventing the formation of plaques. The major pathways for clearance include transport across the Blood-Brain Barrier (BBB), degradation by proteases, and uptake by microglia and astrocytes. One of the key proteins involved clearance is Apolipoprotein E (APOE). APOE is produced by astrocytes and is involved in the transport of lipids in the brain. The ε4 allele of the APOE gene is associated with decreased clearance, while the allele is associated with increased clearance.

References

1. Maccioni, Ricardo B, Juan P Munoz, and Luis Barbeito, et al. "The molecular bases of alzheimer's disease and other neurodegenerative disorders." Arch Med Res 32 (2001): 367-381.

   [Crossref] [Google Scholar] [PubMed]

2. Martin, Joseph B. "Molecular basis of the neurodegenerative disorders." N Engl J Med 340 (1999): 1970-1980.

   [Crossref] [Google Scholar] [PubMed]

3. Cummings, Jeffrey L. "Toward a molecular neuropsychiatry of neurodegenerative diseases." Ann Neurol 54 (2003): 147-154.

   [Crossref] [Google Scholar] [PubMed]

4. Colligris, Pade, Maria Jesus Perez de Lara, Basilio Colligris, and Jesus Pintor, et al. "Ocular manifestations of alzheimer’s and other neurodegenerative diseases: the prospect of the eye as a tool for the early diagnosis of alzheimer’s disease." J Ophthalmol 2018 (2018): 8538573.

   [Crossref] [Google Scholar] [PubMed]

5. Agrawal, Megha, and Abhijit Biswas. "Molecular diagnostics of neurodegenerative disorders." Front Mol Biosci 2 (2015): 54.

   [Crossref] [Google Scholar] [PubMed]

6. Siew, Jian Jing, Yijuang Chern, Kay-Hooi Khoo, and Takashi Angata, et al. "Roles of siglecs in neurodegenerative diseases." Mol Aspects Med 90 (2023): 101141.

   [Crossref] [Google Scholar] [PubMed]